A Study in Participants With End-Stage Renal Disease

Completed · Phase 2

Conditions studied: Kidney Failure, Chronic

In brief

The purpose of this trial is to explore the effect of LY2127399 on those antibodies that are a barrier to kidney transplant. Transplantation is currently the definitive treatment for End-Stage Renal Disease (ESRD), providing prolonged survival and improved quality of life.

Key facts

Study ID

NCT01200290

Run by

Eli Lilly and Company

People needed

18

Starts

2011-04-01

Expected to finish

2014-03-01

Last updated by the study team

2018-05-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have ESRD and are awaiting kidney transplant
• Have a stable PRA score >50%

You may not qualify if…

• Have had a tonsillectomy
• Have a semi-permanent/tunneled catheter
• Have had intravenous immunoglobulin (IVIg) in the past 6 months
• Have had plasmapheresis in the past 6 months
• Uncontrolled hypertension
• Presence of clinically significant cardiac disease in the past 6 months
• Malignancy in the past 5 years, with the exception of cervical, basal cell and squamous epithelial cell cancers
• Have active or recent infection including herpes zoster or herpes simplex in the last 30 days
• Have evidence or suspicion of active Tuberculosis (TB)
• Have had major surgery in the past 2 months
• Have had a serious infection with recovery in the past 3 months
• Have Hepatitis B or C or have Human Immunodeficiency Virus (HIV)

Where it is running

• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.